What if AI could improve outcomes in the pharmaceutical space? That’s exactly what Toronto’s NetraMark Holdings (NetraMark Holding Stock Quote, Chart, News, Analysts, Financials CSE:AIAI) is about.
Is this a big market? Consider this: According to the American Association of Cancer Research (AACR) the oncology clinical trial market was valued at approximately $12.4-billion (U.S.) in 2022 and is projected to grow to $19.49-billion (U.S.) by 2030. So yeah, improving outcomes in this space would be a huge deal for all involved.
NetraMark Holdings CEO George Achilleos sat down with Amber Mac at Cantech 24 on October 9 in Toronto to talk about how his company proposes to do this.
Achillos says the Ontario-based company focuses on something called “Optimize Response Prediction”. What is that? The CEO explained.
“Pharmaceutical companies run clinical trials,” Achillos said. “Clinical trails fail at a 90 per cent clip. Is there a way to figure out who responds to your drug, who is responding to the placebo or not responding? What’s causing an adverse event? What are the key sub-populations within a clinical trial that are causing these failures? Our AI can ingest live clinical trail data readouts and find those sub-populations and help inform a subsequent phase in a clinical trial for these pharmaceutical companies.”
You can view the entire interview below:
About The Author /
Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
RELATED POSTS
Share
Tweet
ShareTRENDING
All Trending →
HEALWELL AI is a stock you should own, Raymond James says
March 13, 2025
Comment